IMMX
Immix Biopharma Inc
NASDAQ: IMMX · HEALTHCARE · BIOTECHNOLOGY
$10.06
+5.45% today
Updated 2026-08-06
Market cap
$606.54M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.92
Dividend yield
—
52W range
$2 – $12
Volume
1.9M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
3.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →209 stocks currently score above 75
Price targets
Analyst target
$19.91
+97.91%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.82 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-9.86M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $-89.52M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-8.23M | $-15.43M | $-21.61M | $-29.44M | $-10.09M |
| EPS | — | — | — | — | $-0.92 |
| Free cash flow | $-7.41M | $-11.42M | $-15.77M | $-24.66M | $-9.86M |
| Profit margin | 9.19% | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-22 | RACHMAN, ILYA M | Buy | 500,000 | — |
| 2026-05-22 | NG, CAREY | Buy | 12,500 | — |
| 2026-05-22 | NG, CAREY | Buy | 6,250 | — |
Peer comparison
Smart narrative
Immix Biopharma Inc trades at $10.06. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.82, it sits in the safe zone.
Frequently asked questions
What is Immix Biopharma Inc's stock price?
Immix Biopharma Inc (IMMX) trades at $10.06.
Is Immix Biopharma Inc overvalued?
Immix Biopharma Inc carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Immix Biopharma Inc (IMMX)?
The 12-month analyst consensus target is $19.91, about 97.9% above the current $10.06. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Immix Biopharma Inc's Altman Z-Score is 3.82, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-41.47%
Beta0.09
50D MA$9.42
200D MA$7.26
Shares out0.07B
Float0.04B
Short ratio—
Avg volume1.9M
Performance
1 week+9.12%
1 month-22.38%
3 months-2.20%
YTD+78.39%
1 year—
3 years—
5 years—